지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
A 25-year-old man, who was suffered from plaque psoriasis for over 6 years, visited our medical center. He did not respond to previous treatments of conventional therapies, including acitretin, cyclosporine and methotrexate, and ustekinumab. He newly started guselkumab (100mg at week 0 and 4, then 100mg at every 8 weeks in total five injections), but it showed insufficient efficacy. The authors considered switching to ixekizumab and after three injections of ixekizumab (80mg every two weeks with a starting dose of 160mg at week 0), the patients appeared to be mostly improved lesions. Biologics have been established the superior efficacy in patients with moderate- to-severe psoriasis. However, some patients show little efficacy from the beginning or lowered efficacy after successful maintenance. In those cases, experts may consider treatment switching, but there are no evidence-based studies on switching biologics in psoriasis. Herein, we report a case of refractory psoriasis to multiple biologics.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Schon MP / 2005 / Psoriasis / N Engl J Med 352:1899~1912
Voiculescu VM / 2014 / Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications / J Med Life 7:468~471
Gelfand JM / 2006 / Risk of myocardial infarction in patients with psoriasis / JAMA 296:1735~1741
Di Cesare, A / 2009 / The IL-23/Th17 axis in the immunopathogenesis of psoriasis / J Invest Dermatol 129:1339~1350
Papp KA / 2008 / Efficacy and safety of ustekinumab, a human interleukin-12/23monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) / Lancet 371:1675~1684
Voiculescu VM / 2014 / Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications / J Med Life 7:468~471
Gelfand JM / 2006 / Risk of myocardial infarction in patients with psoriasis / JAMA 296:1735~1741
Di Cesare, A / 2009 / The IL-23/Th17 axis in the immunopathogenesis of psoriasis / J Invest Dermatol 129:1339~1350
Papp KA / 2008 / Efficacy and safety of ustekinumab, a human interleukin-12/23monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) / Lancet 371:1675~1684
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
만성신부전이 동반된 판상건선 환자의 생물학적제제 치료 3예
대한건선학회지
2021 .06
-
건선 환자에서 생물학적제제 투여 중 재활성화된 잠복결핵 1예
대한건선학회지
2021 .12
-
건선의 생물학제제 교체치료
대한건선학회지
2018 .01
-
건선 환자에서 Guselkumab 치료 중 발생한 후두암
대한건선학회지
2021 .12
-
Clinical Characteristics of Psoriasis for Initiation of Biologic Therapy: A Cluster Analysis
Annals of Dermatology
2023 .04
-
Psoriasis flares after COVID-19 vaccination: adherence to biologic therapy reduces psoriasis exacerbations: a case-control study
Clinical and Experimental Vaccine Research
2023 .01
-
중등도와 중증의 건선환자에서 생물학제제 치료 후 치료 만족도에 대한 평가
대한건선학회지
2021 .12
-
건선에서 사이클로스포린과 메토트렉세이트의 사용
대한건선학회지
2024 .06
-
한국인 중등증 및 중증 건선 환자에서 Secukinumab과 Guselkumab 치료의 임상적 경험
대한건선학회지
2020 .01
-
Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database
Annals of Dermatology
2017 .01
-
건선 환자에서 생물학적 제제의 치료 순응도에 대한 단일기관, 후향적 연구
대한건선학회지
2024 .06
-
코로나바이러스감염증-19(COVID-19)와 건선 치료에 대한 고찰
대한건선학회지
2020 .01
-
Erythrodermic Psoriasis Treated with Golimumab: A Case Report
Annals of Dermatology
2015 .01
-
Which areas are still left in biologics responsive Korean patients with moderate to severe plaque psoriasis
Annals of Dermatology
2023 .02
-
Ustekinumab으로 성공적으로 치료한 뱀독에 의한 홍색피부건선 1예
대한건선학회지
2020 .01
-
건선 환자에서 생물학적제제(Adalimumab and Guselkumab) 사용 중 발생한 박탈 피부염
대한건선학회지
2020 .01
-
Paradoxical Flare of Psoriasis after Ustekinumab Therapy
Annals of Dermatology
2017 .01
-
Basic Therapeutic Approach for Patients with Plaque Psoriasis: Korean Expert Consensus Using the Modified Delphi Method
Annals of Dermatology
2023 .06
-
건선 연구에서 건선 피부 모델의 역할
대한건선학회지
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0